Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 230,370,298 papers from all fields of science
Search
Sign In
Create Free Account
PCNA extractable nuclear Ab:PrThr:Pt:Ser:Ord:IA
Known as:
PCNA ??? ? ??:????:????:??:????:???????
, PCNA anticorps:Arbitraire/Volume:Ponctuel:Sérum:Qualitatif:Enzymoimmunoanalyse
, ENA PCNA Ac Ser Ql EIA
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Antibodies
Extractable nuclear antibody
Immunoassay method
Serology (antibodies and most antigens except blood bank and infectious agents)
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
[Candesartan inhibits the angiotensin II-induced proliferation and migration of rat thoracic aortic smooth muscle A7r5 cells and its mechanism].
Ziting Dang
,
Aimei Zhang
,
+5 authors
J. Si
Xi bao yu fen zi mian yi xue za zhi = Chinese…
2019
Corpus ID: 109940952
Objective To investigate the effect of candesartan on angiotensin II (Ang II)-induced proliferation and migration of vascular…
Expand
2017
2017
ALDH2 genes are negatively correlated with natural deastringency in Chinese PCNA persimmon (Diospyros kaki Thunb.)
Jun-Chi Xu
,
Jin-Ge Ding
,
+4 authors
Z. Luo
Tree Genetics & Genomes
2017
Corpus ID: 255133458
Chinese pollination-constant and non-astringent persimmon (C-PCNA) has important application values in the genetic improvement of…
Expand
2017
2017
TROMBOCITOPENIA ASSOCIADA A ALTERAÇÕES ULTRASSONOGRÁFICAS ESPLÊNICAS PROLIFERATIVAS: REVISÃO
J. F. Moraes
2017
Corpus ID: 187729403
A prevalencia dos tumores em caes e gatos tem aumentado nas ultimas decadas. Essa condicao pode resultar de um aumento real na…
Expand
2015
2015
High Expression of IncRNA-PCNA-AS1 in Human Gastric Cancer and its Clinical Significances.
Y. Dang
,
Yingchao Wang
,
Xiaojuan Ouyang
,
Lie Wang
,
Qiaojia Huang
Clinical Laboratory
2015
Corpus ID: 29728151
BACKGROUND Long noncoding RNAs (IncRNAs) have been demonstrated to be associated with human cancer. However, the clinical value…
Expand
2008
2008
Genetische Polymorphismen in den DNA-Reparaturenzymen ERCC1, XPC, XPF und PCNA und ihre Assoziation zu Larynxkarzinomen
E. Weber
2008
Corpus ID: 83660372
Review
2006
Review
2006
PCNA-LI, Ki-67 Immunostaining, p53 Activity and Histopathological Variables in Predicting the Clinical Outcome in Patients with Parathyroid Carcinoma
F. Lumachi
,
M. Ermani
,
+5 authors
G. Favia
2006
Corpus ID: 41024871
Parathyroid carcinoma is uncommon and no reliable histological markers are available for predicting the clinical outcome of…
Expand
2002
2002
Anagrelide-induzierte Veränderungen der Megakaryopoiese bei der Therapie thrombozythämischer chronischer myeloproliferativer Erkrankungen
T. J.
,
K. H.
,
S. A.
Der Pathologe
2002
Corpus ID: 22074248
ZusammenfassungThrombozythämisch verlaufende Formen chronischer myeloproliferativer Erkrankungen wie die chronische idiopathische…
Expand
1997
1997
Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct.
Takayuki Suto
,
T. Sugai
,
+4 authors
Kazuyoshi Saito
Oncology
1997
Corpus ID: 46877243
We used an immunohistochemical method to determine the concentrations of p53 and proliferating cell nuclear antigen (PCNA) to…
Expand
1996
1996
声帯前癌病変の免疫組織化学的検討 - PCNA, MIB-1 抗体を用いて -
浦野 誠
,
岩田 重信
,
+7 authors
伯野 卓
1996
Corpus ID: 82186939
1995
1995
[Value of monoclonal antibodies (PC 10, MIB1, p53 and LeuM 1) for assessing the prognosis of patients with squamous epithelial carcinoma of the larynx after partial laser resection].
R. Hake
,
H. Eckel
,
E. von Pritzbuer
,
P. Volling
,
J. Thiele
Der Pathologe
1995
Corpus ID: 12501041
An immunohistochemical analysis with monoclonal antibodies against Ki-67 (MIB 1), PCNA (PC10), p53 and Lewis X antigen was…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE